Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Drug Development for Select Diseases

View through CrossRef
Background: Central Council for Research in Ayurvedic Sciences (CCRAS) is actively involved in the scientific process of drug development adopting prevalent guidelines such as good clinical practices guidelines for Ayurveda, Siddha, Unani (ASU) drugs (GCP-ASU), Ministry of AYUSH and National ethical guidelines for Bio-medical Research (ICMR), WHO guidelines for traditional medicines, etc. Drug developed: Till date, 11 technologies have been developed and commercialized by transferring to the Industry through National Research Development Corporation (NRDC), Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India, for wider public utility including drugs for disease like AYUSH 82 for diabetes, AYUSH-64 for malaria, AYUSH SG for rheumatoid arthritis etc, also 17 drugs for RCH have been developed. Drug development under progress: Various new formulations like AYUSH manas for mental retardation/cognitive deficit, AYUSH QOL 2C for improving quality of life in cancer patients, AYUSH Rasayana (A and B) for Geriatric health, AYUSH C1 oil for wound healing, AYUSH PJ-7 for dengue, AYUSH M-3 for migraine, AYUSH SL for filariasis, AYUSH A for bronchial asthma, AYUSH D for Type II diabetes mellitus, carctol S for ovarian cancer, AYUSH K1 for chronic kidney diseases, AYUSH GMH for non alcoholic fatty liver disease (NAFLD) and AYUSH PTK for hepato-protection as adjuvant to anti tubercular treatment (ATT) have been taken up which are at different phases of drug development. Conclusion: Council is working towards drug development following scientific lines taking leads from LHTs and from classical Ayurveda texts to bring out scientifically validated medicine for use among masses in disease conditions of National importance and is committed to develop and provide treatment and prevention of emerging important lifestyle-related disease and other health requirements.
Title: Drug Development for Select Diseases
Description:
Background: Central Council for Research in Ayurvedic Sciences (CCRAS) is actively involved in the scientific process of drug development adopting prevalent guidelines such as good clinical practices guidelines for Ayurveda, Siddha, Unani (ASU) drugs (GCP-ASU), Ministry of AYUSH and National ethical guidelines for Bio-medical Research (ICMR), WHO guidelines for traditional medicines, etc.
Drug developed: Till date, 11 technologies have been developed and commercialized by transferring to the Industry through National Research Development Corporation (NRDC), Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India, for wider public utility including drugs for disease like AYUSH 82 for diabetes, AYUSH-64 for malaria, AYUSH SG for rheumatoid arthritis etc, also 17 drugs for RCH have been developed.
Drug development under progress: Various new formulations like AYUSH manas for mental retardation/cognitive deficit, AYUSH QOL 2C for improving quality of life in cancer patients, AYUSH Rasayana (A and B) for Geriatric health, AYUSH C1 oil for wound healing, AYUSH PJ-7 for dengue, AYUSH M-3 for migraine, AYUSH SL for filariasis, AYUSH A for bronchial asthma, AYUSH D for Type II diabetes mellitus, carctol S for ovarian cancer, AYUSH K1 for chronic kidney diseases, AYUSH GMH for non alcoholic fatty liver disease (NAFLD) and AYUSH PTK for hepato-protection as adjuvant to anti tubercular treatment (ATT) have been taken up which are at different phases of drug development.
Conclusion: Council is working towards drug development following scientific lines taking leads from LHTs and from classical Ayurveda texts to bring out scientifically validated medicine for use among masses in disease conditions of National importance and is committed to develop and provide treatment and prevention of emerging important lifestyle-related disease and other health requirements.

Related Results

Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Illicit drug use and prescription drug misuse among young adult medical marijuana patients and non-patient users in Los Angeles
Illicit drug use and prescription drug misuse among young adult medical marijuana patients and non-patient users in Los Angeles
Introduction: Drug use, including marijuana use, illicit drug use and prescription drug misuse, and mental health comorbidity among young adults are pressing public health concerns...
Clinically significant of drug-drug interactions among children: a review
Clinically significant of drug-drug interactions among children: a review
Drug-drug interactions among children are a getting along concern in health care settings, specifically intensive care units, as sources of adverse drug events that may affect pati...
A REVIEW ON DEVELOPMENT OF COLON TARGETED DRUG DELIVERY SYSTEM
A REVIEW ON DEVELOPMENT OF COLON TARGETED DRUG DELIVERY SYSTEM
The purpose of this review was to select a promising drug delivery system for colon diseases. This review covers the development of Colon Targeted Drug Delivery System (CTDDS) usin...
Pharmacological Review of Drug Interactions
Pharmacological Review of Drug Interactions
Drug interaction (DI) occurs when the effects of one drug are altered by the presence of another drug, herbal medicine, foods, drink or by some environmental or chemical agents”. A...

Back to Top